HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to ...

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral BI 1815368 from Boehringer Ingelheim aims to ...